Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial
ConclusionsThere was no improvement in the response rates, progression-free survival, and overall survival on adding aspirin to EOX chemotherapy in locally advanced and metastatic gastric cancer in an unselected population. A further role of PI3K mutation as a biomarker needs to be evaluated in this setting.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Aspirin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Radiology | Statistics | Study | Toxicology | Xeloda